Intarcia licenses Numab's autoimmune therapy

Ahead of an NDA resubmission for its Type II diabetes therapy, Intarcia exercised an option to license from Numab exclusive, worldwide rights to autoimmune disorder therapy, ND016. ND016 is a trispecific antibody fragment that blocks IL-17A and TNFα, and binds to serum albumin.

Numab Therapeutics AG (Pfäffikon, Switzerland) will receive licensing payments of up to CHF70 million ($69.9 million) and is eligible for up to double-digit tiered royalties...